We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold TMO Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Thermo Fisher's organic revenue growth accelerated to 6% in Q3 2026, led by pharma and biotech.
Bioproduction demand, expanded manufacturing capabilities and margin gains support TMO's growth prospects.
Thermo Fisher repaid $1.1 billion in debt and completed $4 billion in share repurchases in H1 2026.
Thermo Fisher Scientific Inc. (TMO - Free Report) is well-positioned for growth in the coming quarters, supported by accelerating demand across pharma, biotech and industrial markets, and improving organic revenues. The company’s bioproduction business gains traction from biologics demand and expanded manufacturing support capabilities. Thermo Fisher's debt management efforts and substantial share repurchase highlight its focus on balance sheet strength and capital returns. However, macroeconomic challenges and intense competition could pressure its performance.
Over the past year, shares of this Zacks Rank #3 (Hold) company have gained 20.6% compared with the 3.1% rise of the industry and the S&P 500 composite’s gain of 8%.
The renowned medical and laboratory equipment provider has a market capitalization of $257.42 billion. With an earnings yield of 3.6%, it significantly outperforms the industry’s negative 2.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.2%.
Let’s take a closer look.
Upsides for TMO
Strength in End Markets: Thermo Fisher continues to gain share as customer activity recovers across its major end markets. In the third quarter of 2026, pharma and biotech delivered high-single-digit growth, up from mid-single-digit growth in the second quarter. Performance was led by the pharma services and clinical research businesses, as well as the research and safety market channel. Industrial and applied also grew in the high single digits, supported by electron microscopy demand.
Academic and government revenues remained flat despite good performance in chromatography and mass spectrometry, while diagnostics and healthcare grew in the low single digits. North America and Europe each advanced in the mid-single digits, while Asia Pacific, including China, grew in the low double digits. Organic revenue growth accelerated to 6% from 5% in the second quarter.
Image Source: Zacks Investment Research
Bioproduction Business on the Rise: Thermo Fisher’s bioproduction franchise continues to benefit from demand for tools and services used in biologic drug development and manufacturing. Life Sciences Solutions posted 1% organic growth in the third quarter of 2026, following 3% growth in the second quarter, with bioproduction remaining the primary contributor. The segment's adjusted operating margin expanded 20 basis points (bps) year over year to 37.6%, supported by productivity gains despite an unfavorable mix and the impact of the filtration acquisition.
Thermo Fisher is expanding customer support through its flagship U.S. Bioprocess Design Center in Massachusetts, where teams collaborate on process development, manufacturing optimization and commercial scale-up. The filtration and separation acquisition from Solventum extends the company's capabilities across bioproduction workflows.
Solvency Position and Buyback: Thermo Fisher ended the third quarter of 2026 with $6.1 billion in cash and short-term investments and $41.4 billion in total debt. Gross debt to adjusted EBITDA improved to 3.4X from 3.6X at the end of the second quarter, while net leverage declined to 2.9X from 3.3X. The company also repaid approximately $1.1 billion of senior notes during the quarter, reflecting its focus on debt management following recent acquisitions. Thermo Fisher also completed $4 billion in share repurchases during the first half of 2026 and continues to expect approximately $700 million in dividends for the full year.
Thermo Fisher’s Key Concerns
Macroeconomic Risks Remain: Thermo Fisher remains exposed to changes in customer funding, capital spending and global economic conditions. Despite improving customer activity, demand remains uneven across end markets. Academic and government revenues were flat in the third quarter of 2026, reflecting subdued spending in this market. Tariffs, inflation and geopolitical disruptions can also increase input and operating costs. Although adjusted operating margin expanded 120 bps in the quarter, approximately 50 bps came from largely nonrecurring tariff refunds. Sustaining margin growth will require continued productivity gains, favorable demand and effective cost management.
Tough Competitive Pressure: Thermo Fisher faces competition from scientific instrument manufacturers, diagnostics providers, laboratory distributors and biopharma service companies. Rivals may introduce alternative technologies, offer lower pricing or bundle products and services more aggressively. Thermo Fisher must sustain product innovation, competitive pricing and effective commercialization across its broad portfolio. Failure to keep pace with technological advances or changing customer preferences could weaken its competitive position. Slower adoption of new products and increased pricing competition could constrain market share gains, revenue growth and operating profitability over time.
TMO Stock Estimate Trend
The Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has increased 0.5% in the past 30 days to $25.26.
The Zacks Consensus Estimate for 2026 revenues is pegged at $48.02 billion, implying 7.8% year-over-year growth.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 10.6% compared with the industry’s 2.8% yield. Shares of the company have dropped 28.1% compared with the industry’s 19.1% decline over the past year. PAHC’s earnings outpaced estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 12.43%.
IDEXX Laboratories, carrying a Zacks Rank #2, has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have plunged 4.8% against the industry’s 3% growth over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 7% against the industry’s negative 2.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.2%. GMED shares have dropped 17.7% compared with the industry’s 3% gain over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Should You Continue to Hold TMO Stock in Your Portfolio?
Key Takeaways
Thermo Fisher Scientific Inc. (TMO - Free Report) is well-positioned for growth in the coming quarters, supported by accelerating demand across pharma, biotech and industrial markets, and improving organic revenues. The company’s bioproduction business gains traction from biologics demand and expanded manufacturing support capabilities. Thermo Fisher's debt management efforts and substantial share repurchase highlight its focus on balance sheet strength and capital returns. However, macroeconomic challenges and intense competition could pressure its performance.
Over the past year, shares of this Zacks Rank #3 (Hold) company have gained 20.6% compared with the 3.1% rise of the industry and the S&P 500 composite’s gain of 8%.
The renowned medical and laboratory equipment provider has a market capitalization of $257.42 billion. With an earnings yield of 3.6%, it significantly outperforms the industry’s negative 2.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.2%.
Let’s take a closer look.
Upsides for TMO
Strength in End Markets: Thermo Fisher continues to gain share as customer activity recovers across its major end markets. In the third quarter of 2026, pharma and biotech delivered high-single-digit growth, up from mid-single-digit growth in the second quarter. Performance was led by the pharma services and clinical research businesses, as well as the research and safety market channel. Industrial and applied also grew in the high single digits, supported by electron microscopy demand.
Academic and government revenues remained flat despite good performance in chromatography and mass spectrometry, while diagnostics and healthcare grew in the low single digits. North America and Europe each advanced in the mid-single digits, while Asia Pacific, including China, grew in the low double digits. Organic revenue growth accelerated to 6% from 5% in the second quarter.
Image Source: Zacks Investment Research
Bioproduction Business on the Rise: Thermo Fisher’s bioproduction franchise continues to benefit from demand for tools and services used in biologic drug development and manufacturing. Life Sciences Solutions posted 1% organic growth in the third quarter of 2026, following 3% growth in the second quarter, with bioproduction remaining the primary contributor. The segment's adjusted operating margin expanded 20 basis points (bps) year over year to 37.6%, supported by productivity gains despite an unfavorable mix and the impact of the filtration acquisition.
Thermo Fisher is expanding customer support through its flagship U.S. Bioprocess Design Center in Massachusetts, where teams collaborate on process development, manufacturing optimization and commercial scale-up. The filtration and separation acquisition from Solventum extends the company's capabilities across bioproduction workflows.
Solvency Position and Buyback: Thermo Fisher ended the third quarter of 2026 with $6.1 billion in cash and short-term investments and $41.4 billion in total debt. Gross debt to adjusted EBITDA improved to 3.4X from 3.6X at the end of the second quarter, while net leverage declined to 2.9X from 3.3X. The company also repaid approximately $1.1 billion of senior notes during the quarter, reflecting its focus on debt management following recent acquisitions. Thermo Fisher also completed $4 billion in share repurchases during the first half of 2026 and continues to expect approximately $700 million in dividends for the full year.
Thermo Fisher’s Key Concerns
Macroeconomic Risks Remain: Thermo Fisher remains exposed to changes in customer funding, capital spending and global economic conditions. Despite improving customer activity, demand remains uneven across end markets. Academic and government revenues were flat in the third quarter of 2026, reflecting subdued spending in this market. Tariffs, inflation and geopolitical disruptions can also increase input and operating costs. Although adjusted operating margin expanded 120 bps in the quarter, approximately 50 bps came from largely nonrecurring tariff refunds. Sustaining margin growth will require continued productivity gains, favorable demand and effective cost management.
Tough Competitive Pressure: Thermo Fisher faces competition from scientific instrument manufacturers, diagnostics providers, laboratory distributors and biopharma service companies. Rivals may introduce alternative technologies, offer lower pricing or bundle products and services more aggressively. Thermo Fisher must sustain product innovation, competitive pricing and effective commercialization across its broad portfolio. Failure to keep pace with technological advances or changing customer preferences could weaken its competitive position. Slower adoption of new products and increased pricing competition could constrain market share gains, revenue growth and operating profitability over time.
TMO Stock Estimate Trend
The Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has increased 0.5% in the past 30 days to $25.26.
The Zacks Consensus Estimate for 2026 revenues is pegged at $48.02 billion, implying 7.8% year-over-year growth.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 10.6% compared with the industry’s 2.8% yield. Shares of the company have dropped 28.1% compared with the industry’s 19.1% decline over the past year. PAHC’s earnings outpaced estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 12.43%.
PAHC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
IDEXX Laboratories, carrying a Zacks Rank #2, has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have plunged 4.8% against the industry’s 3% growth over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 7% against the industry’s negative 2.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.2%. GMED shares have dropped 17.7% compared with the industry’s 3% gain over the past year.